Exelixis (NASDAQ:EXEL – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Valuation & Earnings
This table compares Exelixis and ProQR Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exelixis | $2.50 billion | 6.74 | $782.57 million | $3.34 | 20.66 |
| ProQR Therapeutics | $18.36 million | 8.09 | -$47.73 million | ($0.46) | -3.07 |
Exelixis has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
85.3% of Exelixis shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Exelixis and ProQR Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exelixis | 35.45% | 45.54% | 33.90% |
| ProQR Therapeutics | -205.69% | -72.78% | -36.78% |
Analyst Recommendations
This is a summary of recent recommendations for Exelixis and ProQR Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exelixis | 1 | 10 | 6 | 1 | 2.39 |
| ProQR Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
Exelixis presently has a consensus target price of $58.62, indicating a potential downside of 15.05%. ProQR Therapeutics has a consensus target price of $7.60, indicating a potential upside of 439.01%. Given ProQR Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Exelixis.
Risk and Volatility
Exelixis has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.
Summary
Exelixis beats ProQR Therapeutics on 9 of the 13 factors compared between the two stocks.
About Exelixis
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
About ProQR Therapeutics
ProQR Therapeutics N.V. is a biotechnology company developing RNA-based medicines for genetic diseases. Its research centers on Axiomer, a platform designed to make targeted changes to RNA using the body’s naturally occurring editing machinery. Founded in 2012 and based in Leiden, the Netherlands, ProQR initially focused on RNA therapies for inherited retinal disorders, including Usher syndrome and Leber congenital amaurosis. The company later broadened its emphasis to RNA editing and continues to develop potential treatments for genetic conditions.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
